ATE296305T1 - Antioxidantien mit spezifischer wirkung auf mitochondrien - Google Patents

Antioxidantien mit spezifischer wirkung auf mitochondrien

Info

Publication number
ATE296305T1
ATE296305T1 AT98961702T AT98961702T ATE296305T1 AT E296305 T1 ATE296305 T1 AT E296305T1 AT 98961702 T AT98961702 T AT 98961702T AT 98961702 T AT98961702 T AT 98961702T AT E296305 T1 ATE296305 T1 AT E296305T1
Authority
AT
Austria
Prior art keywords
compounds
mitochondria
antioxidants
antioxidant
specific effect
Prior art date
Application number
AT98961702T
Other languages
English (en)
Inventor
Michael Patrick Murphy
Robin A J Smith
Original Assignee
Antipodean Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antipodean Biotechnology Ltd filed Critical Antipodean Biotechnology Ltd
Application granted granted Critical
Publication of ATE296305T1 publication Critical patent/ATE296305T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/54Quaternary phosphonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00Dyes not provided for by a single group of this subclass
    • C09B69/001Dyes containing an onium group attached to the dye skeleton via a bridge

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AT98961702T 1997-11-25 1998-11-25 Antioxidantien mit spezifischer wirkung auf mitochondrien ATE296305T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ32925597 1997-11-25
PCT/NZ1998/000173 WO1999026954A1 (en) 1997-11-25 1998-11-25 Mitochondrially targeted antioxidants

Publications (1)

Publication Number Publication Date
ATE296305T1 true ATE296305T1 (de) 2005-06-15

Family

ID=19926531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98961702T ATE296305T1 (de) 1997-11-25 1998-11-25 Antioxidantien mit spezifischer wirkung auf mitochondrien

Country Status (12)

Country Link
EP (1) EP1047701B1 (de)
JP (1) JP4590523B2 (de)
CN (1) CN1318434C (de)
AT (1) ATE296305T1 (de)
AU (2) AU1696499A (de)
CA (1) CA2311318C (de)
DE (1) DE69830338T2 (de)
DK (1) DK1047701T3 (de)
ES (1) ES2244104T3 (de)
NZ (1) NZ505352A (de)
PT (1) PT1047701E (de)
WO (2) WO1999026582A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319131A1 (en) 1998-01-26 1999-07-29 Walter H. Moos Mitochondria protecting agents for treating mitochondria associated diseases
CA2354743A1 (en) * 2001-08-07 2003-02-07 University Of Otago Mitochondrially targeted antioxidants
CA2397684A1 (en) 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
JP4648319B2 (ja) 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
EP1664069B8 (de) * 2003-08-22 2015-07-01 Antipodean Pharmaceuticals, Inc. Als auf die mitochondrien zielende antioxidationsmittel verwendete mitochinonderivate
NZ528966A (en) * 2003-10-17 2006-11-30 Otago Innovation Ltd Peptide nucleic acid conjugates and uses thereof
WO2005097812A1 (en) 2004-04-09 2005-10-20 Valorisation-Recherche, Société en Commandite Phosphonium salts derivatives and their use as solubility controlling auxiliaries
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
US9045505B2 (en) 2006-09-28 2015-06-02 University Of Otago Nitric oxide donors
EA200900583A1 (ru) 2006-10-20 2009-08-28 Общество С Ограниченной Ответственностью "Митотехнология" Композиция для регенерации, стимуляции роста и адаптации растений к различным стрессовым факторам
EA200900582A1 (ru) 2006-10-20 2009-08-28 Общество С Ограниченной Ответственностью "Митотехнология" Фармацевтические композиции для профилактики и лечения глазных патологий
WO2008094062A1 (en) * 2007-01-29 2008-08-07 Limited Liability Company 'mitotechnology' Pharmaceutical compositions useful for preventing and treating oncological diseases
EP2145623A4 (de) * 2007-01-29 2010-10-27 Ltd Liability Company Mitotech Pharmazeutische und kosmetische zusammensetzungen zur beschleunigten heilung von wunden und anderen oberflächenschäden
WO2008127138A1 (fr) * 2007-04-11 2008-10-23 Limited Liability Company 'mitotechnology' Composition visant à ralentir le vieillissement et à allonger la durée de vie de l'organisme et utilisation de cette composition
WO2009005386A1 (en) * 2007-06-29 2009-01-08 Limited Liability Company 'mitotechnology' Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
KR101715631B1 (ko) * 2008-04-01 2017-03-13 안티포딘 파마슈티칼스, 인코포레이티드 피부 관리를 위한 조성물 및 방법
WO2010056145A1 (ru) 2008-11-12 2010-05-20 Общество С Ограниченной Ответственностью "Митотехнология" Способ умеренного повышения протонной проводимости биологических мембран при помощи митохондриально- адресованных делокализованных катионов
AU2009347921B8 (en) 2009-06-10 2014-07-24 Mitotech Sa Pharmaceutical composition for use in medical and veterinary ophthalmology
BR112012011197A2 (pt) 2009-11-13 2020-10-20 Obschestvo S Ogranichennoi Otvetsvennostyu "Mitotekh" subtâncias farmacêuticas com base em antioxidantes direcionados à mitocôndria
EP2714024B1 (de) 2011-06-03 2018-10-03 Mitotech SA Orale formulierungen aus auf mitochondrien gerichteten antioxidantien sowie herstellung und verwendung davon
WO2015063553A2 (en) * 2013-04-11 2015-05-07 Mitotech S.A. Mitochondrially-targeted timoquinones and toluquinones
CA2932548C (en) 2014-01-30 2020-10-27 F. Hoffmann-La Roche Ag Stabilization of whole blood at room temperature
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
CN105833289B (zh) * 2016-05-30 2019-04-09 上海交通大学 一种线粒体靶向的纳米药物递送系统及其制备方法与应用
CN110799516A (zh) * 2017-04-20 2020-02-14 来兴泰德基金会 作为抗癌剂的包含鏻离子的阿奇霉素衍生物
WO2018193114A1 (en) * 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Triphenylphosphonium-tethered tetracycyclines for use in treating cancer
CA3060892A1 (en) 2017-04-20 2018-10-25 Rising Tide Foundation Azithromycin derivatives containing a phosphonium ion as anticancer agents
WO2018193113A1 (en) * 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Phosphonium-ion tethered tetracycline drugs for treatment of cancer
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
EP3612177A4 (de) 2017-04-21 2021-01-13 Lunella Biotech, Inc. Targeting von hypoxischen krebsstammzellen (cscs) mit doxycyclin: implikationen zur verbesserung der anti-angiogenesetherapie
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
WO2019002936A2 (en) 2017-06-26 2019-01-03 Mitotech S.A. SET OF COMPOUNDS TARGETING MITOCHONDRIA
KR102854338B1 (ko) 2017-06-26 2025-09-03 루넬라 바이오테크 인코포레이티드 미토케토신: 암 세포에서 케톤 대사를 표적화하는 미토콘드리아-기반의 치료제
CN109293698B (zh) * 2018-10-15 2021-02-02 山西大学 一种基于苯并噻唑的线粒体pH荧光探针及其制备方法
CN110016048B (zh) * 2019-04-26 2020-06-30 山东大学 线粒体靶向ir780碘化物的衍生物及制备方法与应用
BR112023018109A2 (pt) 2021-03-10 2023-12-12 Shobhanath Giri Rajan Compostos para tratamento de condições relacionadas ao estresse oxidativo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532667A (en) * 1967-05-31 1970-10-06 Du Pont Polyamides stabilized with phosphonium halides
EP0535283A1 (de) * 1991-10-02 1993-04-07 Merrell Dow Pharmaceuticals Inc. Tocopherol Analoge mit kardioprotektiver Wirkung
CA2354743A1 (en) * 2001-08-07 2003-02-07 University Of Otago Mitochondrially targeted antioxidants

Also Published As

Publication number Publication date
EP1047701A4 (de) 2002-03-27
DK1047701T3 (da) 2005-08-15
AU763179B2 (en) 2003-07-17
AU1696499A (en) 1999-06-15
CA2311318A1 (en) 1999-06-03
NZ505352A (en) 2002-12-20
CN1282334A (zh) 2001-01-31
WO1999026582A2 (en) 1999-06-03
AU1696599A (en) 1999-06-15
CN1318434C (zh) 2007-05-30
CA2311318C (en) 2011-11-01
EP1047701A1 (de) 2000-11-02
JP4590523B2 (ja) 2010-12-01
ES2244104T3 (es) 2005-12-01
WO1999026954A1 (en) 1999-06-03
EP1047701B1 (de) 2005-05-25
DE69830338T2 (de) 2006-02-02
DE69830338D1 (de) 2005-06-30
JP2001524483A (ja) 2001-12-04
PT1047701E (pt) 2005-10-31

Similar Documents

Publication Publication Date Title
DE69830338D1 (de) Antioxidantien mit spezifischer wirkung auf mitochondrien
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
BR9905977A (pt) Moduladores de ccr5
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
MX9303598A (es) Conjugados polimeros de taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2171533T3 (es) Composiciones que contienen nebivolol micronizado.
BR9917007A (pt) Moduladores de ccr5
ES2130452T3 (es) Derivados de ciclobutano utilizados como inhibidores de la escualeno-sintetasa y de la farnesiltransferasa proteica.
LU91145I9 (de)
ES2162304T3 (es) Preparaciones cosmeticas y/o farmaceuticas.
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
PT97905A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados da cistina
CA2119853A1 (fr) Nouvelles pyridothiadiazines, leurs procedes de preparation, et les compositions pharmaceutiques qui les contiennent
EP0830456A4 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
NO303783B1 (no) Substituerte aminofosfonatderivater og farmas°ytiske preparater derav
MX9202544A (es) Compuestos de diaminoftalimidas substituidas y analogas, procedimiento para su preparacion y preparados farmaceuticos que los contienen.
ES2077549T1 (es) Composiciones dermatologicas que contienen derivados de estilbeno para la proteccion frente a la radiacion uv.
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
AR012546A1 (es) Utilizacion de al menos un compuesto seleccionado entre el grupo que comprende los sogaoles y los gingeroles para la preparacion de una composiciondesodorante, sogaol, extracto bruto y extracto purificado que contiene el sogaol y la composicion desodorante obtenida.
DE69414810D1 (de) Rapamycin-Zubereitungen zur oralen Verabreichung
BR9911250A (pt) Processo para preparação de compostos
MX9300840A (es) Compuestos farmaceuticos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
PT745081E (pt) Derivados de dissulfureto de inda-2-mercaptoacetilamida uteis como inibidores da encefalinase
CA2137889A1 (fr) Nouveaux analogues de l'eburnane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1047701

Country of ref document: EP

EEIH Change in the person of patent owner